Skip to main content
Clinical Trials/NCT04672278
NCT04672278
Completed
Not Applicable

A Randomized, Double-Blind, Placebo-Controlled Cross-Over Study to Evaluate the Safety, Lipid-Lowering Effect and Hypotensive Effect of Shanzha Fruit Drink in Patients With Mild to Moderate Hyperlipidemia

Chinese University of Hong Kong1 site in 1 country72 target enrollmentJanuary 2, 2019

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Hyperlipidemia
Sponsor
Chinese University of Hong Kong
Enrollment
72
Locations
1
Primary Endpoint
To evaluate the safety of Shanzha Fruit drink in patients with hyperlipidemia by monitoring of liver function tests.
Status
Completed
Last Updated
5 years ago

Overview

Brief Summary

This is a single-center, randomized, double-blind, placebo-controlled, cross-over study. Subjects who meet the inclusion/exclusion criteria will be randomly and alternatively assigned to receive Shanzha fruit drink or placebo drink in the first 2 months or the last two months of the 5 months study period. In between the first and second treatment period, all patients will enter a Washout Period of 4 weeks and during which time patients should not receive any of the study functional fruit drink.

Registry
clinicaltrials.gov
Start Date
January 2, 2019
End Date
October 30, 2020
Last Updated
5 years ago
Study Type
Interventional
Study Design
Crossover
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Brian Tomlinson

Professor

Chinese University of Hong Kong

Eligibility Criteria

Inclusion Criteria

  • • Total Cholesterol between 200-300 mg/dl (5.2-7.8 mmol/l).
  • Mean plasma triglyceride \>= 4.5 mmol/l.
  • Diastolic blood pressure 95-100 mm Hg and/or Systolic blood pressure 130-150 mm Hg.
  • Be able to give written informed consent prior to study start and comply with study requirements.

Exclusion Criteria

  • • Total Cholesterol between 200-300 mg/dl (5.2-7.8 mmol/l).
  • Mean plasma triglyceride \< 4.5 mmol/l.
  • Diastolic blood pressure 95-100 mm Hg and/or Systolic blood pressure 130-150 mm Hg.
  • Be able to give written informed consent prior to study start and comply with study requirements.

Outcomes

Primary Outcomes

To evaluate the safety of Shanzha Fruit drink in patients with hyperlipidemia by monitoring of liver function tests.

Time Frame: 5 months.

Alanine transaminase (ALT) levels as the main liver function test will be measured at the start and the end of the study.

To evaluate the hypolipidemic effect of Shanzha Fruit drink in patients with hyperlipidemia

Time Frame: 5 months.

The lipid profile including total cholesterol, HDL cholesterol, LDL-cholesterol and triglycerides will be measured at the start and the end of the study and changes from the baseline to the end of the treatment will be evaluated.

Secondary Outcomes

  • To evaluate the safety of Shanzha Fruit drink in patients with hyperlipidemia by recording any adverse events reported by the study subjects or noted by the investigator.(5 months.)
  • To evaluate the hypotensive effect of Shanzha Fruit Drink(5 months.)

Study Sites (1)

Loading locations...

Similar Trials